Previous results from Anitua and colleagues showed that the intranasal administration of PRGF-Endoret® reduced AD related neuropathological hallmarks, including Aβ accumulation and tau hyper-phosphorylation, and improved cognitive functions in amyloid precursor protein/ presenilin 1 (APP/PS1) mice [25,26]. This evidence concerns the gene MAPT and Alzheimer disease.